AveXis Inc. (NASDAQ:AVXS) traded up 5.1% on Tuesday . The company traded as high as $39.63 and last traded at $38.91, with a volume of 195,907 shares trading hands. The stock had previously closed at $37.03.

A number of equities research analysts recently weighed in on the stock. Zacks Investment Research raised shares of AveXis from a “sell” rating to a “hold” rating in a research report on Thursday, May 26th. Goldman Sachs Group Inc. lifted their price objective on shares of AveXis from $28.00 to $47.00 and gave the company a “buy” rating in a research note on Friday, May 13th. Jefferies Group lowered shares of AveXis from a “buy” rating to a “hold” rating and lifted their price objective for the company from $39.00 to $42.00 in a research note on Wednesday, June 22nd. They noted that the move was a valuation call. Finally, Chardan Capital restated a “buy” rating and issued a $60.00 price objective on shares of AveXis in a research note on Monday, May 9th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $43.80.

The company’s 50-day moving average price is $41.30 and its 200-day moving average price is $30.31. The firm’s market cap is $896.13 million.

AveXis (NASDAQ:AVXS) last announced its quarterly earnings data on Thursday, May 12th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by $0.89. Equities research analysts anticipate that AveXis Inc. will post ($4.00) EPS for the current year.

AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.